Optogenetics
Optogenetics enables precise control of brain activity using light, offering a powerful approach to neuromodulation. We are harnessing this technology to build a clinical platform aimed at bringing lasting relief for patients with severe neurological disorders.
How it works
Light-Activated Proteins for Precision Neuromodulation
01.
We use gene therapy to introduce light-sensitive proteins, called opsins, in targeted neurons.
Our platform is built on eOPN3, a novel bistable inhibitory G protein-coupled receptor (GPCR) opsin developed at the Weizmann Institute of Science with transformative potential for human clinical applications.
02.
Once introduced to the brain, eOPN3 is expressed throughout the targeted neurons, including their cell bodies and projections.
03.
Neurons communicate with each other by sending electrochemical signals through tiny connections called synapses. When activated by light, eOPN3 silences neural activity at the targeted synapses, rapidly shutting down pathological communication between neurons - while leaving unaffected neurons untouched.
04.
eOPN3 works by leveraging a natural G-protein mediated signalling pathway to inhibit neurotransmitter release, providing a precise and tuneable mechanism for therapeutic intervention.
Our Innovative Platform
By inserting eOPN3 into targeted brain regions and delivering light on demand to calm overactivity, we restore balance to the brain exactly when and where it is needed.
Neurological conditions disrupt specific cells and pathways in the brain – but most current treatments act broadly, leading to limited benefits and unwanted side effects. Modulight Biotherapeutics' approach combines the power of light-based technology and the strength of next-generation GPCR-opsins to enable precision neuromodulation of the affected cells and pathways – offering a groundbreaking approach to treating complex neurological disorders.
Our therapy is disease mechanism-agnostic, which means it can be applied across a wide range of conditions where excessive brain activity drives symptoms. Our early preclinical studies show that this approach offers promising results in models of pain, epilepsy, and movement disorders. These findings establish a path toward a versatile and tuneable therapeutic modality that could transform the lives of millions of people affected by debilitating neurological disorders.